Drugs / Torasemide
Torasemide
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07201584 | Sep → Dec 2025 overdue | — | Berlin-Chemie Menarini | Recruiting | No outcome recorded |
| Phase 1 | NCT01276288 | Jan → Jun 2011 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06413082 | Feb 2021 → Jul 2023 | essential hypertension | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT03354897 | Apr 2017 → Oct 2021 | hypertensive disorder | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 4 | NCT02087332 | Apr 2014 → May 2015 | heart failure, hypertensive disorder | Society of Specialists in Heart Failure | Unknown | No outcome recorded |
| Phase 4 | NCT01942109 | Sep 2013 → Dec 2017 | heart failure | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT01549158 | Feb → Oct 2012 | heart failure | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 4 | NCT00409942 | Mar 2007 → Jun 2009 | congestive heart failure | Ferrer Internacional S.A. | Completed | No outcome recorded |
| Phase 4 | NCT00334386 | Apr 2005 → Feb 2006 | hypertensive disorder | Ferrer Internacional S.A. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06670534 Comparator | Jan 2025 → Jul 2026 overdue | — | Jemincare | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02644616 Comparator | Nov 2014 → Dec 2016 | heart failure, tricuspid valve insufficiency | Shanghai Chest Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Torasemide | “loop diuretics such as furosemide and torasemide” NCT07335900 ↗ |
| Known as | Britomar | “Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and...” NCT02087332 ↗ |
| Known as | Diuver | “Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch,...” NCT02087332 ↗ |
| Known as | TOR | “This study investigated potential pharmacokinetic drug-drug interactions between empagliflozin and hydrochlorothiazide (HCTZ) or torasemide (TOR).” PMID 25636696 ↗ Jan 2015 |
| Known as | Torasemide Prolonged release:Sutril neo | “Torasemide Prolonged release:Sutril neo” NCT00409942 ↗ |
| Known as | torsemide | “This prospective, multicenter, genotype-blinded trial evaluated torasemide (torsemide) efficacy on systolic blood pressure (SBP) reduction over 16 weeks in nondiabetic,...” PMID 39077768 ↗ Jul 2024 |
| Known as | Unat 10 | “Unat® 10 tablets (Torasemide 10 mg)” NCT07201584 ↗ |
| Action | Inhibit | “it inhibits the Na+/K+/2Cl- transport!system” NCT00334386 ↗ |
| Route | Oral | “Single oral dose of torasemide PR 10 mg” NCT01549158 ↗ |